The recent emergence and widespread adoption of potent anti-obesity medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and dual incretin agonists such as tirzepatide, have created new, non-surgical pathways capable of achieving substantial weight loss outcomes, thus prompting a reevaluation of the traditional obesity treatment landscape. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.